Top 10 Questions on Biomarkers in Early Alzheimer’s Disease
Improving Diagnosis and Use of Targeted Therapies
Diagnostic performance of plasma pTau 217, pTau 181, Aβ 1-42 and Aβ 1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease.
Arranz J, Zhu N, Rubio-Guerra S, et al. Res Sq. 2023. [preprint available December 13, 2023]
The Alzheimer's disease clinical spectrum: diagnosis and management.
Atri A. Med Clin North Am. 2019;103(2):263-293.
CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer's disease.
Barthélemy NR, Saef B, Li Y, et al. Nat Aging. 2023;3(4):391-401.
Neuropathological stageing of Alzheimer-related changes.
Braak H, Braak E. Acta Neuropathol. 1991;82(4):239-259.
Alzheimer’s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline.
Bucci M, Chiotis K, Nordberg A, et al. Mol Psychiatry. 2021;26(10):5888-5898.
MRI or 18F-FDG PET for brain age gap estimation: links to cognition, pathology, and Alzheimer disease progression.
Doering E, Antonopoulos G, Hoenig M, et al. J Nucl Med. 2024;65(1):147-155.
Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: the role of CSF biomarkers during the evolution of diagnostic criteria.
Dulewicz M, Kulczyńska-Przybik A, Mroczko P, et al. Int J Mol Sci. 2022;23(15):8598.
The probabilistic model of Alzheimer disease: the amyloid hypothesis revised.
Frisoni GB, Altomare D, Thal DR, et al. Nat Rev Neurosci. 2022;23(1):53-66.
A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers.
Jack CR Jr, Bennett DA, Blennow K, et al. Neurology. 2016;87(5):539-547.
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
Jack CR, Jr., Bennett DA, Blennow K, et al. Alzheimers Dement. 2018;14(4):535-562.
Biomarker Changes during 20 Years Preceding Alzheimer’s Disease
Jia J, Ning Y, Chen M, et al. N Engl J Med. 2024;390(8):712-722.
Development of Alzheimer's disease biomarkers: from CSF- to blood-based biomarkers.
Mankhong S, Kim S, Lee S, et al. Biomedicines. 2022;10(4):850.
Plasma biomarkers of alzheimer's disease: a review of available assays, recent developments, and implications for clinical practice.
Pais MV, Forlenza OV, Diniz BS. J Alzheimers Dis Rep. 2023;7(1):355-380.
Cerebrospinal fluid immune dysregulation during healthy brain aging and cognitive impairment.
Piehl N, van Olst L, Ramakrishnan A, et al. Cell. 2022;185(26):5028-5039.e5013.
Donanemab in Early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial.
Sims JR, Zimmer JA, Evans CD, et al. JAMA. 2023;330(6):512-527.
Lecanemab in early Alzheimer’s disease.
van Dyck CH, Swanson CJ, Aisen P, et al. N Engl J Med. 2023;388(1):9-21.
Clinical Practice Guidelines
Lecanemab: appropriate use recommendations.
Cummings J, Apostolova L, Rabinovici GD, et al. J Prev Alzheimers Dis. 2023;10(3):362-377.
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer’s Association Workgroup
National Institute on Aging and the Alzheimer’s Association (NIA-AA)
International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer’s disease.
Tian M, Civelek AC, Carrio I, et al. Eur J Nucl Med Mol Imaging. 2022;49(3):895-904.
International Nuclear Medicine Consensus on the clinical use of amyloid positron emission tomography in Alzheimer’s disease.
Tian M, Zuo C, Civelek AC, et al. Phenomics. 2023;3(4):375-389.
Patient and Caregiver Resources
AD8 dementia screening interview
Alzheimer’s Association
The Alzheimer’s Questionnaire
Mini-Mental State Exam (MMSE) Alzheimer’s / dementia test: administration, accuracy and scoring
Montreal Cognitive Assessment Test (MoCA) for dementia & Alzheimer’s
Standardized Mini-Cog© Instrument
Top 10 Questions on Biomarkers in Early Alzheimer’s Disease
Improving Diagnosis and Use of Targeted Therapies
| Faculty: | R. Scott Turner, PhD, MD, FANA, FAAN; James E. Galvin, MD, MPH |
| Release: | 03/28/2024 |
| Expiration: | 03/28/2025 |
